{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T17:40:01Z","timestamp":1779212401240,"version":"3.51.4"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100017547","name":"Jiangsu Association for Science and Technology","doi-asserted-by":"publisher","award":["JSKJZK2023041"],"award-info":[{"award-number":["JSKJZK2023041"]}],"id":[{"id":"10.13039\/501100017547","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002857","name":"China Pharmaceutical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","seizure-journal.com","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure: European Journal of Epilepsy"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.seizure.2023.07.003","type":"journal-article","created":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T01:10:26Z","timestamp":1688519426000},"page":"203-211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Real-world safety of Lacosamide: A pharmacovigilance study based on spontaneous reports in the FDA adverse event reporting system"],"prefix":"10.1016","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8775-6334","authenticated-orcid":false,"given":"Pengcheng","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7157-3100","authenticated-orcid":false,"given":"Mengjiao","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoli","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenbing","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2023.07.003_bib0001","first-page":"37","article-title":"Study on analytical method of particle size of Lacosamide active pharmaceutical ingredient","volume":"15","author":"Dayong","year":"2022","journal-title":"Mod Chem Res"},{"issue":"20","key":"10.1016\/j.seizure.2023.07.003_bib0002","first-page":"30","article-title":"Efficacy of Lacosamide in the treatment of children with focal seizures","volume":"19","author":"Mingming","year":"2022","journal-title":"Med Innov China"},{"issue":"18","key":"10.1016\/j.seizure.2023.07.003_bib0003","first-page":"3142","article-title":"Efficacy and safety of lacosamide in the additive treatment of children with focal epilepsy","volume":"51","author":"Bei","year":"2022","journal-title":"Chongqing Med J"},{"key":"10.1016\/j.seizure.2023.07.003_bib0004","unstructured":"Jin Yong. Anti-epileptic drugs old and new camp PK who is the number one player?. Med Econ News. 2021-10-25: 005."},{"issue":"09","key":"10.1016\/j.seizure.2023.07.003_bib0005","first-page":"159","article-title":"Clinical efficacy of Lacosamid additive in treatment of focal epilepsy in children","volume":"51","author":"Huicong","year":"2022","journal-title":"J Med Res"},{"issue":"02","key":"10.1016\/j.seizure.2023.07.003_bib0006","first-page":"147","article-title":"Advances in the use of lacosamide in elderly patients with epilepsy","volume":"7","author":"Zhenyu","year":"2021","journal-title":"J Epilepsy"},{"issue":"16","key":"10.1016\/j.seizure.2023.07.003_bib0007","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1097\/WNR.0000000000001123","article-title":"Lacosamide modulates collapsin response mediator protein 2 and inhibits mossy fiber sprouting after kainic acid-induced status epilepticus","volume":"29","author":"Wang","year":"2018","journal-title":"Neuroreport"},{"key":"10.1016\/j.seizure.2023.07.003_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.108128","article-title":"Lacosamide as first add-on or conversion monotherapy: a retrospective real-life study","volume":"122","author":"Casciato","year":"2021","journal-title":"Epilep Behav: E&B"},{"issue":"2","key":"10.1016\/j.seizure.2023.07.003_bib0009","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s12035-014-8775-9","article-title":"Specific binding of lacosamide to collapsin response mediator protein 2 (CRMP2) and direct impairment of its canonical function: implications for the therapeutic potential of lacosamide","volume":"51","author":"Wilson","year":"2015","journal-title":"Mol Neurobiol"},{"issue":"10","key":"10.1016\/j.seizure.2023.07.003_bib0010","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1136\/jnnp-2020-323524","article-title":"Efficacy and safety of adjunctive lacosamide in the treatment of primary generalised tonic-clonic seizures: a double-blind, randomised, placebo-controlled trial","volume":"91","author":"Vossler","year":"2020","journal-title":"J Neurol Neurosurg Psychiatr"},{"issue":"9","key":"10.1016\/j.seizure.2023.07.003_bib0011","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1080\/17425255.2017.1360278","article-title":"Pharmacokinetic drug evaluation of lacosamide for the treatment of partial-onset seizures","volume":"13","author":"de Biase","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.seizure.2023.07.003_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2019.05.027","article-title":"Healthcare resource utilization and costs before and after lacosamide initiation as adjunctive therapy among patients with epilepsy in the United States","volume":"99","author":"Fishman","year":"2019","journal-title":"Epilep Behav: E&B"},{"issue":"1","key":"10.1016\/j.seizure.2023.07.003_bib0013","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1684\/epd.2020.1136","article-title":"Cardioembolic acute cerebral micro-infarcts in the context of atrial fibrillation after low-dose intravenous infusion of lacosamide","volume":"22","author":"Corbellini","year":"2020","journal-title":"Epilep Disord: Int Epilep J Videot"},{"issue":"6","key":"10.1016\/j.seizure.2023.07.003_bib0014","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s12012-018-9467-x","article-title":"Complete atrioventricular block in an elderly patient treated with low-dose lacosamide","volume":"18","author":"Lachuer","year":"2018","journal-title":"Cardiovasc Toxicol"},{"issue":"6","key":"10.1016\/j.seizure.2023.07.003_bib0015","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jemermed.2019.01.018","article-title":"Lacosamide Overdose: A Case of QRS Prolongation and Seizure","volume":"56","author":"Ng","year":"2019","journal-title":"J Emerg Med"},{"key":"10.1016\/j.seizure.2023.07.003_bib0016","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.seizure.2018.10.005","article-title":"HyperCKemia associated with lacosamide therapy in an elderly patient with focal onset epilepsy","volume":"63","author":"Matsudaira","year":"2018","journal-title":"Seizure"},{"issue":"6","key":"10.1016\/j.seizure.2023.07.003_bib0017","doi-asserted-by":"crossref","first-page":"e729","DOI":"10.1097\/MJT.0000000000000745","article-title":"Lacosamide: associated hyponatremia","volume":"25","author":"Gupta","year":"2018","journal-title":"Am J Therapeut"},{"issue":"3","key":"10.1016\/j.seizure.2023.07.003_bib0018","doi-asserted-by":"crossref","first-page":"394","DOI":"10.5507\/bp.2014.006","article-title":"The effect of lacosamide on bone tissue in orchidectomised male albino Wistar rats","volume":"159","author":"Simko","year":"2015","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"key":"10.1016\/j.seizure.2023.07.003_bib0019","article-title":"Effectiveness and tolerability of lacosamide in children with drug resistant epilepsy","volume":"21","author":"Driessen","year":"2023","journal-title":"Epilep Behav Rep"},{"key":"10.1016\/j.seizure.2023.07.003_bib0020","doi-asserted-by":"crossref","DOI":"10.1111\/epi.17187","article-title":"Safety and tolerability of short-term infusions of intravenous lacosamide in pediatric patients with epilepsy: an open-label, phase 2\/3 trial","author":"Farkas","year":"2022","journal-title":"Epilepsia Open"},{"issue":"10","key":"10.1016\/j.seizure.2023.07.003_bib0021","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s40263-022-00955-9","article-title":"Psychobehavioural and cognitive adverse events of anti-seizure medications for the treatment of developmental and epileptic encephalopathies","volume":"36","author":"Strzelczyk","year":"2022","journal-title":"CNS Drug"},{"key":"10.1016\/j.seizure.2023.07.003_bib0022","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.seizure.2015.07.001","article-title":"Efficacy and safety of lacosamide as first add-on or later adjunctive treatment for uncontrolled partial-onset seizures: a multicentre open-label trial","volume":"31","author":"Zadeh","year":"2015","journal-title":"Seizure"},{"issue":"2","key":"10.1016\/j.seizure.2023.07.003_bib0023","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/14740338.2020.1713089","article-title":"The adverse-effect profile of lacosamide","volume":"19","author":"Li","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.seizure.2023.07.003_bib0024","first-page":"euac203","article-title":"Epileptic seizure-induced syncopal asystole reversed by lacosamide: a case report","author":"Fitouchi","year":"2022","journal-title":"Europac: Eur Pac, Arrhythm Card Electrophysiol: J Work Gr Card Pac, Arrhythm Card Cellul Electrophysiol Eur Soc Cardiol"},{"issue":"1","key":"10.1016\/j.seizure.2023.07.003_bib0025","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s12883-021-02253-1","article-title":"Lacosamide-induced sinus node dysfunction followed by severe agranulocytosis","volume":"21","author":"Shibata","year":"2021","journal-title":"BMC Neurol"},{"issue":"1","key":"10.1016\/j.seizure.2023.07.003_bib0026","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug Reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"10.1016\/j.seizure.2023.07.003_bib0027","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction Reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"10.1016\/j.seizure.2023.07.003_bib0028","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.seizure.2023.07.003_bib0029","unstructured":"designated-medical-event-dme-list_en.xlsx. [EB\/OL]. https:\/\/view.officeapps.live.com\/op\/view.aspx?src=https%3A%2F%2Fwww.ema.europa.eu%2Fen%2Fdocuments%2Fother%2Fdesignated-medical-event-dme-list_en.xlsx&wdOrigin=BROWSELINK."},{"issue":"1","key":"10.1016\/j.seizure.2023.07.003_bib0030","first-page":"146","article-title":"Data mining and analysis of adverse drug events signals for levetiracetam based on FAERS database","volume":"46","author":"Xinming","year":"2023","journal-title":"Drug Evaluat Res"},{"key":"10.1016\/j.seizure.2023.07.003_bib0031","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.seizure.2014.11.007","article-title":"Lacosamide as adjunctive therapy in refractory epilepsy in adults: a systematic review","volume":"25","author":"Paquette","year":"2015","journal-title":"Seizure"},{"issue":"4","key":"10.1016\/j.seizure.2023.07.003_bib0032","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1684\/epd.2015.0782","article-title":"Efficacy and safety of lacosamide as an adjunctive therapy for refractory focal epilepsy in paediatric patients: a retrospective single-centre study","volume":"17","author":"Toupin","year":"2015","journal-title":"Epilep Disord: Int Epilep J Videot"},{"issue":"4","key":"10.1016\/j.seizure.2023.07.003_bib0033","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/ana.10473","article-title":"A novel mechanism underlying drug resistance in chronic epilepsy","volume":"53","author":"Remy","year":"2003","journal-title":"Ann Neurol"},{"issue":"38","key":"10.1016\/j.seizure.2023.07.003_bib0034","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.2174\/1381612822666160810150416","article-title":"ABC Transporters and Drug Resistance in Patients with Epilepsy","volume":"22","author":"Feldmann","year":"2016","journal-title":"Curr Pharm Des"},{"issue":"5","key":"10.1016\/j.seizure.2023.07.003_bib0035","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/FPC.0b013e3282f85e36","article-title":"Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs","volume":"18","author":"Hung","year":"2008","journal-title":"Pharmacogenet Genom"},{"issue":"5","key":"10.1016\/j.seizure.2023.07.003_bib0036","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1528-1167.2007.01302.x","article-title":"ABC transporters during epilepsy and mechanisms underlying multidrug resistance in refractory epilepsy","volume":"48","author":"Lazarowski","year":"2007","journal-title":"Epilepsia"},{"issue":"11","key":"10.1016\/j.seizure.2023.07.003_bib0037","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1345\/aph.1M303","article-title":"Lacosamide: an adjunctive agent for partial-onset seizures and potential therapy for neuropathic pain","volume":"43","author":"Harris","year":"2009","journal-title":"Ann Pharmacother"},{"issue":"12","key":"10.1016\/j.seizure.2023.07.003_bib0038","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s40263-013-0123-5","article-title":"Lacosamide: a review of its use as adjunctive therapy in the management of partial-onset seizures","volume":"27","author":"Hoy","year":"2013","journal-title":"CNS Drug"},{"key":"10.1016\/j.seizure.2023.07.003_bib0039","unstructured":"LACOSAMIDE TABLETS. LACOSAMIDE film coated tablet, for oral use, CV Initial U.S. Approval: 2008[EB\/OL]. https:\/\/nctr-crs.fda.gov\/fdalabel\/services\/spl\/set-ids\/f047077c-2ac7-30d0-e053-2995a90ae429\/spl-doc?hl=lacosamide."},{"issue":"6","key":"10.1016\/j.seizure.2023.07.003_bib0040","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1111\/epi.12108","article-title":"Sinus node dysfunction: an adverse effect of lacosamide","volume":"54","author":"Chinnasami","year":"2013","journal-title":"Epilepsia"},{"issue":"12","key":"10.1016\/j.seizure.2023.07.003_bib0041","doi-asserted-by":"crossref","first-page":"736","DOI":"10.5414\/CP203813","article-title":"Lacosamide-induced recurrent ventricular fibrillation: a case report","volume":"58","author":"Eleftheriou","year":"2020","journal-title":"Int J Clin Pharmacol Therapeut"},{"issue":"Pt A","key":"10.1016\/j.seizure.2023.07.003_bib0042","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.yebeh.2015.09.006","article-title":"Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials","volume":"52","author":"Biton","year":"2015","journal-title":"Epilep Behav: E&B"},{"issue":"12","key":"10.1016\/j.seizure.2023.07.003_bib0043","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1111\/epi.13224","article-title":"A noninterventional study evaluating the effectiveness and safety of lacosamide added to monotherapy in patients with epilepsy with partial-onset seizures in daily clinical practice: the VITOBA study","volume":"56","author":"Runge","year":"2015","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.seizure.2023.07.003_bib0044","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/epi4.12522","article-title":"Long-term safety and tolerability of lacosamide monotherapy in patients with epilepsy: results from a multicenter, open-label trial","volume":"6","author":"Ben-Menachem","year":"2021","journal-title":"Epilepsia Open"},{"issue":"5","key":"10.1016\/j.seizure.2023.07.003_bib0045","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/AJP.0b013e318196d2b6","article-title":"Efficacy and safety of lacosamide in diabetic neuropathic pain: an 18-week double-blind placebo-controlled trial of fixed-dose regimens","volume":"25","author":"Wymer","year":"2009","journal-title":"Clin J Pain"},{"issue":"8","key":"10.1016\/j.seizure.2023.07.003_bib0046","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.jpain.2009.01.322","article-title":"Lacosamide in painful diabetic neuropathy: an 18-week double-blind placebo-controlled trial","volume":"10","author":"Shaibani","year":"2009","journal-title":"J Pain"},{"issue":"08","key":"10.1016\/j.seizure.2023.07.003_bib0047","first-page":"763","article-title":"Treatment analysis of a case of severe acute pancreatitis combined with toxic epidermolysis bullosa death","volume":"35","author":"Hui","year":"2015","journal-title":"Chin Hosp Pharm J"},{"key":"10.1016\/j.seizure.2023.07.003_bib0048","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000335627","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"97","author":"Harr","year":"2012","journal-title":"Chem Immunol Allergy"},{"issue":"3","key":"10.1016\/j.seizure.2023.07.003_bib0049","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1684\/epd.2014.0667","article-title":"Lacosamide-induced rash","volume":"16","author":"Koubeissi","year":"2014","journal-title":"Epilep Disord: Int Epilep J Videot"},{"issue":"1","key":"10.1016\/j.seizure.2023.07.003_bib0050","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1172\/JCI119505","article-title":"Direct, MHC-dependent presentation of the drug sulfamethoxazole to human alphabeta T cell clones","volume":"100","author":"Schnyder","year":"1997","journal-title":"J Clin Invest"},{"issue":"8","key":"10.1016\/j.seizure.2023.07.003_bib0051","doi-asserted-by":"crossref","first-page":"683","DOI":"10.7326\/0003-4819-139-8-200310210-00012","article-title":"Delayed drug hypersensitivity reactions","volume":"139","author":"Pichler","year":"2003","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.seizure.2023.07.003_bib0052","first-page":"72","article-title":"Pathogenesis of antiepileptics-induced drug eruption","volume":"7","author":"Pei-pei","year":"2013","journal-title":"Chin J Aller Clin Immunol"},{"issue":"08","key":"10.1016\/j.seizure.2023.07.003_bib0053","first-page":"476","article-title":"Overview of the new anti-epileptic drug Lacosamide","volume":"19","author":"Fengmei","year":"2010","journal-title":"Chin J Pharmacoepidemiol"},{"issue":"11","key":"10.1016\/j.seizure.2023.07.003_bib0054","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1111\/epi.17395","article-title":"Lacosamide effects on placental carriers of essential compounds in comparison with valproate: studies in perfused human placentas","volume":"63","author":"Berman","year":"2022","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.seizure.2023.07.003_bib0055","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.pjnns.2017.03.003","article-title":"Lacosamide during pregnancy and breastfeeding","volume":"51","author":"Lattanzi","year":"2017","journal-title":"Neurol Neurochir Pol"},{"issue":"9","key":"10.1016\/j.seizure.2023.07.003_bib0056","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1248\/yakushi.22-00044","article-title":"Case report on a woman with epilepsy who took lacosamide during pregnancy and gave birth to a healthy infant","volume":"142","author":"Kitamura","year":"2022","journal-title":"Yakugaku Zasshi\u00a0: J Pharmaceut Soc Jpn"},{"issue":"6","key":"10.1016\/j.seizure.2023.07.003_bib0057","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1684\/epd.2022.1492","article-title":"Breastfeeding while on treatment with antiseizure medications: a systematic review from the ILAE Women Task Force","volume":"24","author":"Tomson","year":"2022","journal-title":"Epilep Disord"},{"key":"10.1016\/j.seizure.2023.07.003_bib0058","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.yebeh.2016.07.007","article-title":"Randomized double-blind comparison of cognitive and EEG effects of lacosamide and carbamazepine","volume":"62","author":"Meador","year":"2016","journal-title":"Epilep Behav: E&B"},{"issue":"6","key":"10.1016\/j.seizure.2023.07.003_bib0059","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/ane.12372","article-title":"Cognitive effects of lacosamide as adjunctive therapy in refractory epilepsy","volume":"131","author":"IJff","year":"2015","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.seizure.2023.07.003_bib0060","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.yebeh.2016.04.049","article-title":"The effects of lacosamide on cognition, quality-of-life measures, and quality of life in patients with refractory partial epilepsy","volume":"61","author":"Lancman","year":"2016","journal-title":"Epilep Behav: E&B"},{"issue":"1","key":"10.1016\/j.seizure.2023.07.003_bib0061","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/epi.16748","article-title":"Cognitive decline in older adults with epilepsy: the Cardiovascular Health Study","volume":"62","author":"Choi","year":"2021","journal-title":"Epilepsia"},{"issue":"10","key":"10.1016\/j.seizure.2023.07.003_bib0062","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1080\/14740338.2022.2054986","article-title":"Dropped head syndrome: a rare adverse drug reaction identified in the FDA adverse event reporting system and review of case reports in the literature","volume":"21","author":"Liu","year":"2022","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.seizure.2023.07.003_bib0063","unstructured":"EMA. Signal management[EB]. European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/human-regulatory\/post-authorisation\/pharmacovigilance\/signal-management."},{"issue":"9","key":"10.1016\/j.seizure.2023.07.003_bib0064","article-title":"MLIP causes recessive myopathy with rhabdomyolysis, myalgia and baseline elevated serum creatine Kinase","volume":"144","author":"Neto","year":"2021","journal-title":"Brain\u00a0: A J Neurol"},{"issue":"1","key":"10.1016\/j.seizure.2023.07.003_bib0065","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2174\/1381612827666210804095300","article-title":"RYR1-related rhabdomyolysis: a spectrum of hypermetabolic states due to ryanodine receptor dysfunction","volume":"28","author":"Kruijt","year":"2022","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.seizure.2023.07.003_bib0066","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.seizure.2018.10.005","article-title":"HyperCKemia associated with lacosamide therapy in an elderly patient with focal onset Epilepsy","volume":"63","author":"Matsudaira","year":"2018","journal-title":"Seiz- Eur J Epilep"},{"issue":"3","key":"10.1016\/j.seizure.2023.07.003_bib0067","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0303-8467(93)90122-W","article-title":"Rhabdomyolysis: a review of the Literature","volume":"95","author":"Poels","year":"1993","journal-title":"Clin Neurol Neurosurg"},{"issue":"8","key":"10.1016\/j.seizure.2023.07.003_bib0068","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.nmd.2014.05.005","article-title":"Rhabdomyolysis: review of the Literature","volume":"24","author":"Zutt","year":"2014","journal-title":"Neuromuscul Disord: NMD"},{"issue":"3","key":"10.1016\/j.seizure.2023.07.003_bib0069","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.coph.2012.04.002","article-title":"Drug induced rhabdomyolysis","volume":"12","author":"Hohenegger","year":"2012","journal-title":"Curr Opin Pharmacol"},{"issue":"1","key":"10.1016\/j.seizure.2023.07.003_bib0070","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/MJT.0b013e3181ff7c79","article-title":"Statin-associated rhabdomyolysis with acute renal failure complicated by intradialytic NSTEMI: a review of lipid management Considerations","volume":"20","author":"Kar","year":"2013","journal-title":"Am J Ther"},{"key":"10.1016\/j.seizure.2023.07.003_bib0071","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.116742","article-title":"Racial variations in lacosamide serum concentrations in adult patients with Epilepsy","volume":"412","author":"Zutshi","year":"2020","journal-title":"J Neurol Sci"}],"container-title":["Seizure: European Journal of Epilepsy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131123001863?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131123001863?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T16:51:41Z","timestamp":1722617501000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131123001863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":71,"alternative-id":["S1059131123001863"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2023.07.003","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world safety of Lacosamide: A pharmacovigilance study based on spontaneous reports in the FDA adverse event reporting system","name":"articletitle","label":"Article Title"},{"value":"Seizure: European Journal of Epilepsy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2023.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 British Epilepsy Association. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}